0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Age Related Macular Degeneration Drug Market Research Report 2026
Published Date: 2026-03-27
|
Report Code: QYRE-Auto-8B9447
Home | Market Reports | People & Society
Global Age Related Macular Degeneration Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Age Related Macular Degeneration Drug Market Research Report 2026

Code: QYRE-Auto-8B9447
Report
2026-03-27
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Age Related Macular Degeneration Drug Market Size

The global Age Related Macular Degeneration Drug market was valued at US$ 9116 million in 2025 and is anticipated to reach US$ 13540 million by 2032, at a CAGR of 5.9% from 2026 to 2032.

Age Related Macular Degeneration Drug Market

Age Related Macular Degeneration Drug Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Age Related Macular Degeneration Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Age Related Macular Degeneration Drugs (AMD drugs) are therapeutic solutions developed to address vision loss or blurriness caused by degeneration in the macular region among the elderly. These drugs primarily act through mechanisms such as inhibiting abnormal blood vessel formation, antioxidant protection, inflammation modulation, or improvement of retinal cell metabolism to slow down or reverse the progression of macular degeneration. With the acceleration of population aging and growing awareness of eye health, AMD drugs hold significant clinical value and have become a key focus in ophthalmic drug development and market strategy.In 2024, global Age Related Macular Degeneration Drugs production reached approximately 7.87 million units, with an average global market price of around US$ 1100 perunit.The average gross profit margin of this product is 85%.
The AMD drug market is facing multiple development opportunities. Firstly, the continuous growth of the aging population globally expands the patient base, providing long-term demand support. Secondly, advances in ophthalmic medical technology and improved early diagnostic capabilities facilitate earlier intervention, driving drug usage frequency and market penetration. Additionally, increased public health awareness, the popularization of vision protection concepts, and expanded insurance coverage create new growth drivers for the AMD drug market. Finally, innovation by multinational pharmaceutical companies and local R&D institutions in biopharmaceutical technologies, targeted therapies, and gene therapy accelerates technological support and diversification of products in the market.
Despite significant market potential, AMD drug development faces challenges and risks. Long R&D cycles, high investment costs, and complex clinical trials prolong the time to market for new drugs. Uncertainty in drug efficacy and safety, including potential resistance or adverse reactions in some patients, increases clinical application difficulty. Stricter regulatory policies and differences in drug approval processes across countries may also constrain market expansion. Moreover, competition from generics and pricing pressures pose commercialization risks for high-end innovative drugs.
Downstream demand for AMD drugs shows diversified trends. With an increasing aging population and the popularization of chronic eye disease management concepts, patient demand for early intervention and long-term treatment continues to grow. The rise of ophthalmic specialty hospitals, community healthcare centers, and telemedicine platforms has also expanded drug prescription channels. Patients’ preference for personalized and targeted treatment options drives demand for innovative drugs and combination therapies. Furthermore, with optimized insurance policies and improved social security systems, downstream market affordability and accessibility steadily increase, supporting continued penetration of AMD drugs.
The upstream raw materials for AMD drugs mainly include biopharmaceutical agents, anti-VEGF molecules, protein engineering materials, and small molecule chemical precursors. The stability of raw material supply directly affects drug production and cost control, especially given the high manufacturing complexity of high-purity proteins and bioactive components. Upstream factors such as production technology levels, supply chain diversity, and international trade policies significantly influence drug R&D and manufacturing efficiency. With the improvement of the biopharmaceutical industry chain, standardization and quality control of raw materials have gradually increased, providing support for the reliable supply of AMD drugs.
This report delivers a comprehensive overview of the global Age Related Macular Degeneration Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Age Related Macular Degeneration Drug. The Age Related Macular Degeneration Drug market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Age Related Macular Degeneration Drug market comprehensively. Regional market sizes by Type, by Application, by Clinical Type, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Age Related Macular Degeneration Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Age Related Macular Degeneration Drug Market Report

Report Metric Details
Report Name Age Related Macular Degeneration Drug Market
Accounted market size in 2025 US$ 9116 million
Forecasted market size in 2032 US$ 13540 million
CAGR 5.9%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Lucentis
  • Eylea
  • Avastin
  • Others
Segment by Clinical Type
  • Wet ADM
  • Dry ADM
Segment by Administration Route
  • Intravitreal injection
  • Oral Administration
  • Topical Eye Drops
  • Other
by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Clinical Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Age Related Macular Degeneration Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Age Related Macular Degeneration Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Age Related Macular Degeneration Drug Market growing?

Ans: The Age Related Macular Degeneration Drug Market witnessing a CAGR of 5.9% during the forecast period 2026-2032.

What is the Age Related Macular Degeneration Drug Market size in 2032?

Ans: The Age Related Macular Degeneration Drug Market size in 2032 will be US$ 13540 million.

Who are the main players in the Age Related Macular Degeneration Drug Market report?

Ans: The main players in the Age Related Macular Degeneration Drug Market are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma

What are the Application segmentation covered in the Age Related Macular Degeneration Drug Market report?

Ans: The Applications covered in the Age Related Macular Degeneration Drug Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Age Related Macular Degeneration Drug Market report?

Ans: The Types covered in the Age Related Macular Degeneration Drug Market report are Wet ADM, Dry ADM

1 Age Related Macular Degeneration Drug Market Overview
1.1 Product Definition
1.2 Age Related Macular Degeneration Drug by Type
1.2.1 Global Age Related Macular Degeneration Drug Market Value by Type: 2025 vs 2032
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Others
1.3 Age Related Macular Degeneration Drug by Clinical Type
1.3.1 Global Age Related Macular Degeneration Drug Market Value by Clinical Type: 2025 vs 2032
1.3.2 Wet ADM
1.3.3 Dry ADM
1.4 Age Related Macular Degeneration Drug by Administration Route
1.4.1 Global Age Related Macular Degeneration Drug Market Value by Administration Route: 2025 vs 2032
1.4.2 Intravitreal injection
1.4.3 Oral Administration
1.4.4 Topical Eye Drops
1.4.5 Other
1.5 Age Related Macular Degeneration Drug by Application
1.5.1 Global Age Related Macular Degeneration Drug Market Value by Application: 2025 vs 2032
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Global Age Related Macular Degeneration Drug Market Size Estimates and Forecasts
1.6.1 Global Age Related Macular Degeneration Drug Revenue 2021–2032
1.6.2 Global Age Related Macular Degeneration Drug Sales 2021–2032
1.6.3 Global Age Related Macular Degeneration Drug Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Age Related Macular Degeneration Drug Market Competition by Manufacturers
2.1 Global Age Related Macular Degeneration Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Age Related Macular Degeneration Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Age Related Macular Degeneration Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Age Related Macular Degeneration Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Age Related Macular Degeneration Drug, Product Types and Applications
2.7 Global Key Manufacturers of Age Related Macular Degeneration Drug, Date of Entry into the Industry
2.8 Global Age Related Macular Degeneration Drug Market Competitive Situation and Trends
2.8.1 Global Age Related Macular Degeneration Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Age Related Macular Degeneration Drug Players Market Share by Revenue
2.8.3 Global Age Related Macular Degeneration Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Age Related Macular Degeneration Drug Market Scenario by Region
3.1 Global Age Related Macular Degeneration Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Age Related Macular Degeneration Drug Sales by Region: 2021–2032
3.2.1 Global Age Related Macular Degeneration Drug Sales by Region: 2021–2026
3.2.2 Global Age Related Macular Degeneration Drug Sales by Region: 2027–2032
3.3 Global Age Related Macular Degeneration Drug Revenue by Region: 2021–2032
3.3.1 Global Age Related Macular Degeneration Drug Revenue by Region: 2021–2026
3.3.2 Global Age Related Macular Degeneration Drug Revenue by Region: 2027–2032
3.4 North America Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.4.1 North America Age Related Macular Degeneration Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Age Related Macular Degeneration Drug Sales by Country (2021–2032)
3.4.3 North America Age Related Macular Degeneration Drug Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.5.1 Europe Age Related Macular Degeneration Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Age Related Macular Degeneration Drug Sales by Country (2021–2032)
3.5.3 Europe Age Related Macular Degeneration Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Age Related Macular Degeneration Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Age Related Macular Degeneration Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Age Related Macular Degeneration Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Age Related Macular Degeneration Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.7.1 Latin America Age Related Macular Degeneration Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Age Related Macular Degeneration Drug Sales by Country (2021–2032)
3.7.3 Latin America Age Related Macular Degeneration Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Age Related Macular Degeneration Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Age Related Macular Degeneration Drug Sales by Type (2021–2032)
4.1.1 Global Age Related Macular Degeneration Drug Sales by Type (2021–2026)
4.1.2 Global Age Related Macular Degeneration Drug Sales by Type (2027–2032)
4.1.3 Global Age Related Macular Degeneration Drug Sales Market Share by Type (2021–2032)
4.2 Global Age Related Macular Degeneration Drug Revenue by Type (2021–2032)
4.2.1 Global Age Related Macular Degeneration Drug Revenue by Type (2021–2026)
4.2.2 Global Age Related Macular Degeneration Drug Revenue by Type (2027–2032)
4.2.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2021–2032)
4.3 Global Age Related Macular Degeneration Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Age Related Macular Degeneration Drug Sales by Application (2021–2032)
5.1.1 Global Age Related Macular Degeneration Drug Sales by Application (2021–2026)
5.1.2 Global Age Related Macular Degeneration Drug Sales by Application (2027–2032)
5.1.3 Global Age Related Macular Degeneration Drug Sales Market Share by Application (2021–2032)
5.2 Global Age Related Macular Degeneration Drug Revenue by Application (2021–2032)
5.2.1 Global Age Related Macular Degeneration Drug Revenue by Application (2021–2026)
5.2.2 Global Age Related Macular Degeneration Drug Revenue by Application (2027–2032)
5.2.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2021–2032)
5.3 Global Age Related Macular Degeneration Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Company Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Bayer HealthCare
6.2.1 Bayer HealthCare Company Information
6.2.2 Bayer HealthCare Description and Business Overview
6.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
6.2.5 Bayer HealthCare Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Roche
6.4.1 Roche Company Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Kanghong Pharma
6.5.1 Kanghong Pharma Company Information
6.5.2 Kanghong Pharma Description and Business Overview
6.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
6.5.5 Kanghong Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Age Related Macular Degeneration Drug Industry Chain Analysis
7.2 Age Related Macular Degeneration Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Age Related Macular Degeneration Drug Production Mode & Process Analysis
7.4 Age Related Macular Degeneration Drug Sales and Marketing
7.4.1 Age Related Macular Degeneration Drug Sales Channels
7.4.2 Age Related Macular Degeneration Drug Distributors
7.5 Age Related Macular Degeneration Drug Customer Analysis
8 Age Related Macular Degeneration Drug Market Dynamics
8.1 Age Related Macular Degeneration Drug Industry Trends
8.2 Age Related Macular Degeneration Drug Market Drivers
8.3 Age Related Macular Degeneration Drug Market Challenges
8.4 Age Related Macular Degeneration Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Age Related Macular Degeneration Drug Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Age Related Macular Degeneration Drug Market Value by Clinical Type (US$ Million), 2025 vs 2032
 Table 3. Global Age Related Macular Degeneration Drug Market Value by Administration Route (US$ Million), 2025 vs 2032
 Table 4. Global Age Related Macular Degeneration Drug Market Value by Application (US$ Million), 2025 vs 2032
 Table 5. Global Age Related Macular Degeneration Drug Market Competitive Situation by Manufacturers in 2025
 Table 6. Global Age Related Macular Degeneration Drug Sales (K Dose) of Key Manufacturers (2021–2026)
 Table 7. Global Age Related Macular Degeneration Drug Sales Market Share by Manufacturers (2021–2026)
 Table 8. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 9. Global Age Related Macular Degeneration Drug Revenue Share by Manufacturers (2021–2026)
 Table 10. Global Market Age Related Macular Degeneration Drug Average Price (USD/Unit) of Key Manufacturers (2021–2026)
 Table 11. Global Key Players of Age Related Macular Degeneration Drug, Industry Ranking, 2023 vs 2024 vs 2025
 Table 12. Global Key Manufacturers of Age Related Macular Degeneration Drug, Manufacturing Sites and Headquarters
 Table 13. Global Key Manufacturers of Age Related Macular Degeneration Drug, Product Types and Applications
 Table 14. Global Key Manufacturers of Age Related Macular Degeneration Drug, Date of Entry into the Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Age Related Macular Degeneration Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Age Related Macular Degeneration Drug Revenue, 2025
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Age Related Macular Degeneration Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 19. Global Age Related Macular Degeneration Drug Sales by Region (K Dose), 2021–2026
 Table 20. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2021–2026)
 Table 21. Global Age Related Macular Degeneration Drug Sales by Region (K Dose), 2027–2032
 Table 22. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2027–2032)
 Table 23. Global Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2021–2026
 Table 24. Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2021–2026)
 Table 25. Global Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2027–2032
 Table 26. Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2027–2032)
 Table 27. North America Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 28. North America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
 Table 29. North America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
 Table 30. North America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
 Table 31. North America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
 Table 32. Europe Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 33. Europe Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
 Table 34. Europe Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
 Table 35. Europe Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
 Table 36. Europe Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
 Table 37. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 38. Asia Pacific Age Related Macular Degeneration Drug Sales by Region (K Dose), 2021–2026
 Table 39. Asia Pacific Age Related Macular Degeneration Drug Sales by Region (K Dose), 2027–2032
 Table 40. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2021–2026
 Table 41. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2027–2032
 Table 42. Latin America Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 43. Latin America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
 Table 44. Latin America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
 Table 45. Latin America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
 Table 46. Latin America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
 Table 47. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 48. Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
 Table 49. Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
 Table 50. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
 Table 51. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
 Table 52. Global Age Related Macular Degeneration Drug Sales (K Dose) by Type (2021–2026)
 Table 53. Global Age Related Macular Degeneration Drug Sales (K Dose) by Type (2027–2032)
 Table 54. Global Age Related Macular Degeneration Drug Sales Market Share by Type (2021–2026)
 Table 55. Global Age Related Macular Degeneration Drug Sales Market Share by Type (2027–2032)
 Table 56. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Type (2021–2026)
 Table 57. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Type (2027–2032)
 Table 58. Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2021–2026)
 Table 59. Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2027–2032)
 Table 60. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2021–2026)
 Table 61. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2027–2032)
 Table 62. Global Age Related Macular Degeneration Drug Sales (K Dose) by Application (2021–2026)
 Table 63. Global Age Related Macular Degeneration Drug Sales (K Dose) by Application (2027–2032)
 Table 64. Global Age Related Macular Degeneration Drug Sales Market Share by Application (2021–2026)
 Table 65. Global Age Related Macular Degeneration Drug Sales Market Share by Application (2027–2032)
 Table 66. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Application (2021–2026)
 Table 67. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Application (2027–2032)
 Table 68. Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2021–2026)
 Table 69. Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2027–2032)
 Table 70. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2021–2026)
 Table 71. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2027–2032)
 Table 72. Regeneron Pharmaceuticals Company Information
 Table 73. Regeneron Pharmaceuticals Description and Business Overview
 Table 74. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 75. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product
 Table 76. Regeneron Pharmaceuticals Recent Developments/Updates
 Table 77. Bayer HealthCare Company Information
 Table 78. Bayer HealthCare Description and Business Overview
 Table 79. Bayer HealthCare Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 80. Bayer HealthCare Age Related Macular Degeneration Drug Product
 Table 81. Bayer HealthCare Recent Developments/Updates
 Table 82. Novartis Company Information
 Table 83. Novartis Description and Business Overview
 Table 84. Novartis Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 85. Novartis Age Related Macular Degeneration Drug Product
 Table 86. Novartis Recent Developments/Updates
 Table 87. Roche Company Information
 Table 88. Roche Description and Business Overview
 Table 89. Roche Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 90. Roche Age Related Macular Degeneration Drug Product
 Table 91. Roche Recent Developments/Updates
 Table 92. Kanghong Pharma Company Information
 Table 93. Kanghong Pharma Description and Business Overview
 Table 94. Kanghong Pharma Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 95. Kanghong Pharma Age Related Macular Degeneration Drug Product
 Table 96. Kanghong Pharma Recent Developments/Updates
 Table 97. Key Raw Materials Lists
 Table 98. Raw Materials Key Suppliers Lists
 Table 99. Age Related Macular Degeneration Drug Distributors List
 Table 100. Age Related Macular Degeneration Drug Customers List
 Table 101. Age Related Macular Degeneration Drug Market Trends
 Table 102. Age Related Macular Degeneration Drug Market Drivers
 Table 103. Age Related Macular Degeneration Drug Market Challenges
 Table 104. Age Related Macular Degeneration Drug Market Restraints
 Table 105. Research Programs/Design for This Report
 Table 106. Key Data Information from Secondary Sources
 Table 107. Key Data Information from Primary Sources
 Table 108. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Age Related Macular Degeneration Drug
 Figure 2. Global Age Related Macular Degeneration Drug Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Age Related Macular Degeneration Drug Market Share by Type: 2025 & 2032
 Figure 4. Lucentis Product Picture
 Figure 5. Eylea Product Picture
 Figure 6. Avastin Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Age Related Macular Degeneration Drug Market Value by Clinical Type (US$ Million), 2021–2032
 Figure 9. Global Age Related Macular Degeneration Drug Market Share by Clinical Type: 2025 vs 2032
 Figure 10. Wet ADM Product Picture
 Figure 11. Dry ADM Product Picture
 Figure 12. Global Age Related Macular Degeneration Drug Market Value by Administration Route (US$ Million), 2021–2032
 Figure 13. Global Age Related Macular Degeneration Drug Market Share by Administration Route: 2025 vs 2032
 Figure 14. Intravitreal injection Product Picture
 Figure 15. Oral Administration Product Picture
 Figure 16. Topical Eye Drops Product Picture
 Figure 17. Other Product Picture
 Figure 18. Global Age Related Macular Degeneration Drug Market Value by Application (US$ Million), 2021–2032
 Figure 19. Global Age Related Macular Degeneration Drug Market Share by Application: 2025 & 2032
 Figure 20. Hospitals
 Figure 21. Clinics
 Figure 22. Others
 Figure 23. Global Age Related Macular Degeneration Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 24. Global Age Related Macular Degeneration Drug Market Size (US$ Million), 2021–2032
 Figure 25. Global Age Related Macular Degeneration Drug Sales (K Dose), 2021–2032
 Figure 26. Global Age Related Macular Degeneration Drug Average Price (USD/Unit), 2021–2032
 Figure 27. Age Related Macular Degeneration Drug Report Years Considered
 Figure 28. Age Related Macular Degeneration Drug Sales Share by Manufacturers in 2025
 Figure 29. Global Age Related Macular Degeneration Drug Revenue Share by Manufacturers in 2025
 Figure 30. Top 5 and Top 10 Global Age Related Macular Degeneration Drug Players: Market Share by Revenue in Age Related Macular Degeneration Drug in 2025
 Figure 31. Age Related Macular Degeneration Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 32. Global Age Related Macular Degeneration Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 33. North America Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
 Figure 34. North America Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
 Figure 35. U.S. Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Canada Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Europe Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
 Figure 38. Europe Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
 Figure 39. Germany Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. France Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. U.K. Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Italy Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Russia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Asia Pacific Age Related Macular Degeneration Drug Sales Market Share by Region (2021–2032)
 Figure 45. Asia Pacific Age Related Macular Degeneration Drug Revenue Market Share by Region (2021–2032)
 Figure 46. China Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Japan Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. South Korea Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. India Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Australia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Taiwan Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Indonesia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Thailand Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Malaysia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Philippines Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Latin America Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
 Figure 57. Latin America Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
 Figure 58. Mexico Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. Brazil Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. Argentina Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 61. Middle East and Africa Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
 Figure 62. Middle East and Africa Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
 Figure 63. Turkey Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 64. Saudi Arabia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 65. U.A.E Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 66. Global Sales Market Share of Age Related Macular Degeneration Drug by Type (2021–2032)
 Figure 67. Global Revenue Market Share of Age Related Macular Degeneration Drug by Type (2021–2032)
 Figure 68. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2021–2032)
 Figure 69. Global Sales Market Share of Age Related Macular Degeneration Drug by Application (2021–2032)
 Figure 70. Global Revenue Market Share of Age Related Macular Degeneration Drug by Application (2021–2032)
 Figure 71. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2021–2032)
 Figure 72. Age Related Macular Degeneration Drug Value Chain
 Figure 73. Channels of Distribution (Direct Vs Distribution)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS